menu
    • menu
    [{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"OXS-3550","moa":"CD16","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"Akshaya Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cytovance Biologics \/ Cytovance Biologics ","highestDevelopmentStatusID":"6","companyTruncated":"Cytovance Biologics \/ Cytovance Biologics "},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"GTB-3550","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"GTB-3550 TriKE","moa":"CD16","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cytovance Biologics \/ GT Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Cytovance Biologics \/ GT Biopharma"},{"orgOrder":0,"company":"Cytovance Biologics","sponsor":"GT Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"GTB-3650","moa":"IL-15","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cytovance Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cytovance Biologics \/ Cytovance Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Cytovance Biologics \/ Cytovance Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Cytovance Biologics

    Menu

    Cytovance Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GTB-3650

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : GT Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

                            Details : GTB-3650 is the Company's lead second-generation Tri-Specific Killer Engager TriKE ® program currently in preclinical development for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

                            Brand Name : GTB-3650

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 30, 2022

                            Lead Product(s) : GTB-3650

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : GT Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GTB-3550 TriKE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : GT Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GT Biopharma Transfers TriKE™ Manufacturing To Cytovance Biologics In Preparation For Expanded And Multiple ...

                            Details : Previously, the lead candidate GTB-3550 TriKE™ was manufactured at the University of Minnesota's GMP manufacturing center. GT Biopharma expanded GMP manufacturing agreement with Cytovance Biologics for the manufacture of all TriKEs™.

                            Brand Name : GTB-3550 TriKE

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 18, 2021

                            Lead Product(s) : GTB-3550 TriKE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : GT Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GTB-3550

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : GT Biopharma

                            Deal Size : $6.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GT Biopharma Announces Expanded TriKe(tm) Partnership with Cytovance Biologics

                            Details : Under the terms of the partnership agreement, Cytovance will be the exclusive GMP manufacture for three of the Company's TriKE™ therapeutic product candidates.

                            Brand Name : GTB-3550

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : GTB-3550

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : GT Biopharma

                            Deal Size : $6.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Akshaya Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cytovance Biologics and Akshaya Bio Collaborate to Develop Therapeutics for Treatment of Coronavirus and Hepat...

                            Details : Collaboration to focus on using Akshaya’s proprietary Chimigen® Platform Technology to execute bulk drug products of both COVID-19 and HBV vaccines to be used in Phase I clinical trials by Cytovance.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 23, 2020

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Akshaya Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Cytovance Biologics

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OXS-3550

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : IND Enabling

                            Sponsor : GT Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GT Biopharma and Cytovance Biologics Announce Collaboration for the treatment of coronavirus infection

                            Details : The companies will focus on preparing sufficient quantities of GT's Covid-19 TriKE drug product for preclinical evaluation using Cytovance's E. coli-based Keystone Expression System.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 10, 2020

                            Lead Product(s) : OXS-3550

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : GT Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth